Catalyst Pharmaceuticals Stock Investor Sentiment
| CPRX Stock | USD 14.73 0.37 2.45% |
Slightly above 55% of Catalyst Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Catalyst Pharmaceuticals suggests that many traders are impartial. Catalyst Pharmaceuticals' investor sentiment overview provides quick insight into current market opportunities from investing in Catalyst Pharmaceuticals. The current market sentiment, together with Catalyst Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Catalyst Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Panic Vs Confidence
45
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Catalyst Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Catalyst Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Catalyst Pharmaceuticals stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Catalyst daily returns and investor perception about the current price of Catalyst Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios.
Catalyst Historical Sentiment
Although Catalyst Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Catalyst, such as negative comments on social media and news outlets, may cause fear in the market and push Catalyst Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Catalyst.
Catalyst |
Catalyst Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Catalyst Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Catalyst Pharmaceuticals Historical Investor Sentiment
Investor biases related to Catalyst Pharmaceuticals' public news can be used to forecast risks associated with an investment in Catalyst. The trend in average sentiment can be used to explain how an investor holding Catalyst can time the market purely based on public headlines and social activities around Catalyst Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Catalyst Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Catalyst Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Catalyst Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Catalyst Pharmaceuticals.
Far too much social signal, news, headlines, and media speculation about Catalyst Pharmaceuticals that are available to investors today. That information is available publicly through Catalyst media outlets and privately through word of mouth or via Catalyst internal channels. However, regardless of the origin, that massive amount of Catalyst data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Catalyst Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Catalyst Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Catalyst Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Catalyst Pharmaceuticals alpha.
Catalyst Pharmaceuticals Performance against NYSE Composite
Price Growth (%) |
| Timeline |
1 | Disposition of 2353 shares by Brian Elsbernd of Catalyst Pharmaceuticals subject to Rule 16b-3 | 02/15/2024 |
2 | Exercise or conversion by David Tierney of 4000 shares of Catalyst Pharmaceuticals subject to Rule 16b-3 | 02/16/2024 |
3 | Catalyst Pharmaceuticals, Inc. Short Interest Update | 03/05/2024 |
4 | Santheras Partner Catalyst Pharmaceuticals Launches AGAMREE in the United States | 03/14/2024 |
5 | Acquisition by Donald Denkhaus of 40000 shares of Catalyst Pharmaceuticals at 4.01 subject to Rule 16b-3 | 03/19/2024 |
6 | Investors in Catalyst Pharmaceuticals have seen strong returns of 271 percent over the past three years | 03/22/2024 |
7 | The three-year decline in earnings might be taking its toll on Catalyst Pharmaceuticals shareholders as stock falls 3.9 percent over the past week | 03/27/2024 |
8 | Catalyst Pharmaceuticals executive sells over 400k in company stock | 03/28/2024 |
9 | Acquisition by David Tierney of 25000 shares of Catalyst Pharmaceuticals at 4.01 subject to Rule 16b-3 | 04/08/2024 |
10 | Catalyst Pharmaceutical Misses Q1 Earnings Estimates - Yahoo Movies UK | 04/15/2024 |
11 | Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 | 04/22/2024 |
Check out Catalyst Pharmaceuticals Hype Analysis, Catalyst Pharmaceuticals Correlation and Catalyst Pharmaceuticals Performance. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Catalyst Stock analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Catalyst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.346 | Earnings Share 0.63 | Revenue Per Share 3.747 | Quarterly Revenue Growth 0.82 | Return On Assets 0.1283 |
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.